Please login to the form below

OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy

Written by Gavin Jones, OPEN Health

The FDA has published their industry guidance on the topic of long term follow up (LTFU) post gene therapy. Please see a link to the full guidance below. In summary, they are stipulating that a good proportion of these therapies will require LTFU of up to fifteen years.

This presents significant challenge to manufacturers given that patients will, in that stretch of time, have multiple changes to their care settings and life circumstances. In addition to this, and if these therapies live up to their promise, treated ‘patients’ will potentially become chronically well and keen to disengage from their previous disease state and their healthcare professionals.

This is a significant challenge but achievable! We have already shared our experienced thinking on this topic and a link to our article is provided below. Our recommendations focus on putting the patient at the centre of a solution and wrapping a, digitally enabled, registry solution around thoughtful patient and healthcare professional engagement.

Please read our full thinking below:

Pink divider

Get in touch

If you would like to discuss further please contact our director of rare disease:

29th January 2020


Company Details

OPEN Health

+44 1628 481112

Contact Website

The Weighbridge
Brewery Courtyard
High Street
United Kingdom

Latest content on this profile

Rare Disease Day 2021
To mark Rare Disease Day 2021 on Sunday 28 February, OPEN Health will be intentionally quiet on all LinkedIn channels from 26 February to 1 March in order not to distract from awareness generated by patient groups.
OPEN Health
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health

OPEN Health
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health

OPEN Health
OPEN Health Group Appoints New Leadership

OPEN Health
OPEN VIE and Pharmerit Bring the Best of Both Worlds to Virtual ISPOR Europe 2020
Join OPEN VIE and Pharmerit – an OPEN Health Company at the ISPOR European Virtual Conference from 16-19 November 2020 to see how we are shaping the healthcare industry with innovative research methods and world-class communications.
OPEN Health
OPEN Health brings the Best of Both Worlds to MAPS EMEA 2020

OPEN Health